Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics
(PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced
KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy